I disagree with the other poster who thought SA Neop article was well written. IMO, this was a one sided hatchet job intended to drive the pps down. His analysis of the Lymphoseek pricing and current stock valuation was the only part that I can't call complete garbage. Other than that, it was hardly a fair assessment. We won't have to wait long to see who is right.
What a business, he shorts the stock then gets to write the hatchet job that gives him his chance to cover.
News 
Market Data 
Discover 
